CRL · Charles River Laboratories International, Inc.

The thesis

Charles River Laboratories' case has moved from a demand recovery to a stated multi-year growth plan, and the shares have recovered above the $280 weekly level they lost on 18 September 2026. The 4 November 2026 (estimated) third-quarter report is the next test of whether reported organic growth reaches the 1%–3% the company guided.

The shares closed at $286.83 on 1 October 2026, 3.9% below the 52-week high of $298.58. They rose 23.9% over the three months to that date, and the 14-day relative strength index (RSI, a 0–100 momentum gauge) read 56.7. The 18 September 2026 weekly close of $278.06 had broken the earlier price condition. The 24 September 2026 Investor Day and the analyst target increases that followed have since reversed that move.

The narrative is accelerating again: the Investor Day supplied the first quantified 2030 targets, and at least eight firms raised or reinstated price targets between 25 September 2026 and 30 September 2026.

Bullish and bearish views on Charles River Laboratories International, Inc.

The bull case on Charles River Laboratories International, Inc. (CRL), in brief: Management now publishes 2030 targets. The bear case: Reported revenue still shrinks in 2026.

Bull case

• Management now publishes 2030 targets. At the 24 September 2026 Investor Day, Charles River guided to organic revenue growth of 5%–7% a year over 2027–2030, a non-GAAP operating margin of about 24%, and low-double-digit annual growth in non-GAAP earnings per share, per the company's 8-K. It also targeted at least $300 million of cumulative savings over 2027–2030.
• The 2026 outlook was reiterated. On 24 September 2026 the company reiterated full-year 2026 revenue and non-GAAP earnings guidance of $11.15–$11.45 per share, with a non-GAAP operating margin of 21.0%–21.3%. No cut accompanied the new targets.
• Orders ran ahead of revenue. On 5 August 2026, the Discovery and Safety Assessment (DSA) segment reported second-quarter net bookings of $701 million, net book-to-bill of 1.19 times and backlog of $1.97 billion. Book-to-bill has been above one for three consecutive quarters.
• Analyst targets rose broadly after the event. On 25 September 2026, Baird raised its target to $334, Barclays to $330, Evercore ISI to $330, RBC Capital to $322, TD Cowen to $325 and Deutsche Bank to $320. Jefferies raised to $340 on 28 September 2026, and UBS reinstated a Buy with a $357 target on 30 September 2026.

Bear case

• Reported revenue still shrinks in 2026. Divestitures removed about 7% of 2025 revenue. The company's third-quarter guidance, as summarized by third-party earnings trackers, calls for reported revenue down 4%–6% against organic growth of 1%–3%.
• The recovery is narrow so far. Second-quarter organic growth was 0.1% in the 5 August 2026 results, the first positive reading after a long run of declines. A single positive quarter is too small a sample to confirm a durable trend.
• Margins and earnings quality lag orders. DSA's second-quarter operating margin was 25.6%, down 180 basis points year over year. Full-year GAAP earnings per share guidance was cut to $3.05–$3.35 on 5 August 2026, against non-GAAP guidance of $11.15–$11.45.
• Academic demand remains weak. On 5 August 2026 management said it continues to expect lower research-model volumes in North America, citing constrained academic and government spending under flat National Institutes of Health budgets. Research Models and Services organic revenue fell 1.4% in the second quarter.
• Not every analyst sees much upside. Mizuho kept a Neutral rating on 25 September 2026 and raised its target to $295, 2.8% above the 1 October 2026 close.

Price setup

The 1 October 2026 close of $286.83 sits 3.9% below the 52-week high of $298.58. The shares ended the week of 18 September 2026 at $278.06, 3.1% lower than the current close, with RSI at 39.4. RSI has since recovered to 56.7, which is mid-range rather than stretched.

The 18 September 2026 close of $278.06 is the nearest reference point on the downside. The 52-week high of $298.58 is the nearest on the upside. The three-month gain of 23.9% means a good deal of the August recovery is already in the price.

Crowding evidence is mixed. Analyst targets were raised in a cluster after the Investor Day, which shows broad sell-side agreement but little room for further upgrades. Several August 2026 insider sales ran under pre-existing Rule 10b5-1 plans, which set their timing in advance. The next earnings date, estimated at 4 November 2026, falls just outside the 30-day window.

Catalysts, next 30 days

• No company-scheduled event is confirmed between 2 October 2026 and 1 November 2026. The Investor Day on 24 September 2026 has already occurred.
• ~4 November 2026, est.: third-quarter 2026 results, just outside the window. Third-party trackers cite company guidance of non-GAAP earnings per share of $2.90–$3.00 and organic growth of 1%–3%. DSA book-to-bill and margin are the numbers that settle the case.
• Further analyst target changes and conference appearances are possible before the report, though none is scheduled in the supplied material.

What would change the view

The case breaks if the recovery in orders does not reach revenue and margins: third-quarter organic growth below the guided 1%–3%, DSA net book-to-bill below one, or a second consecutive year-over-year decline in DSA operating margin. Any cut to the reiterated 2026 non-GAAP guidance of $11.15–$11.45 would also undermine the plan presented on 24 September 2026. On price, a daily close below $270 would put the shares under the 18 September 2026 weekly close of $278.06 and erase the post-Investor Day recovery.

What it trades with

Charles River sells preclinical research services and research models to drug developers, so its orders follow biotech funding and pharmaceutical research budgets. Academic and government demand ties it to National Institutes of Health funding. Its cost-saving and portfolio-reshaping plan stems from the May 2025 Elliott cooperation agreement, and the 24 September 2026 targets are the first long-term reset under that arrangement. Moves in biotech funding sentiment and in peer contract research names are the most likely sources of shared price swings.